Market Closed -
Sao Paulo
04:07:00 2024-04-24 pm EDT
5-day change
1st Jan Change
28.78
BRL
-0.43%
+1.70%
-19.50%
Sales 2024 *
8.68B
1.69B
Sales 2025 *
9.6B
1.86B
Capitalization
18.22B
3.54B
Net income 2024 *
1.88B
364M
Net income 2025 *
2.22B
432M
EV / Sales 2024 *
2.97
x
Net Debt
2024
*
7.53B
1.46B
Net Debt
2025
*
6.35B
1.23B
EV / Sales 2025 *
2.56
x P/E ratio 2024 *
9.76
x
P/E ratio 2025 *
8.67
x
Employees
10,301
Yield 2024 *
4.34%
Yield 2025 *
5.12%
Free-Float
58.51%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Transcript : Hypera S.A., Q4 2023 Earnings Call, Mar 14, 2024
Mar. 14
Hypera S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 13
CI
Hypera S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 13
CI
Transcript : Hypera S.A., Q3 2023 Earnings Call, Oct 27, 2023
23-10-27
Hypera S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-26
CI
Transcript : Hypera S.A., Q2 2023 Earnings Call, Jul 28, 2023
23-07-28
Hypera S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-07-27
CI
Pacific Shuanglin Bio-pharmacy Signs Drug Supply, Distribution Deal With Brazil’s Hypera Pharma
23-05-05
MT
Transcript : Hypera S.A., Q1 2023 Earnings Call, Apr 28, 2023
23-04-28
Hypera S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-27
CI
Clever Leaves Teams Up With Hypera Pharma for Brazil Expansion Project
23-04-18
MT
Transcript : Hypera S.A., 2022 Earnings Call, Feb 17, 2023
23-02-17
Hypera S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-15
CI
Hypera S.A.(BOVESPA:HYPE3) added to Brazil IBRX 50 Index
22-12-30
CI
Hypera S.A.(BOVESPA:HYPE3) added to Brazil Corporate Sustainability Index
22-12-30
CI
More news
1 day -0.43%
1 week +1.70%
Current month -12.60%
1 month -15.63%
3 months -10.65%
6 months -15.43%
Current year -19.50%
More quotes
Managers
Title Age Since
Director of Finance/CFO
36
22-02-23
Compliance Officer
40
07-12-31
Investor Relations Contact
42
15-12-31
Members of the board
Title Age Since
Director/Board Member
74
-
Director/Board Member
58
-
Director/Board Member
49
-
More insiders
Date
Price
Change
Volume
24-04-24
28.78
-1.07%
2,948,000
24-04-23
29.09
+0.31%
3,109,900
24-04-22
29
+2.29%
4,235,000
24-04-19
28.35
-0.18%
4,854,100
24-04-18
28.4
+0.35%
4,884,400
Delayed Quote
Sao Paulo, April 24, 2024 at 04:07 pm EDT
More quotes
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
More about the company
Last Close Price
28.78
BRL
Average target price
42.28
BRL
Spread / Average Target
+46.92%
Consensus
1st Jan change
Capi.
-19.50% 3.53B +25.61% 660B +25.87% 562B -5.24% 358B +16.49% 322B +8.28% 297B +7.09% 219B -9.12% 196B +5.01% 199B -8.75% 149B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1